OC
ORKA

Oppenheimer & Co’s Oruka Therapeutics ORKA Stock Holding History

Oppenheimer & Co’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20
Closed -$35K – 1474
2015
Q2 		$35K Hold
20
– – ﹤0.01% 1451
2015
Q1 		$24K Buy
+20
New +$23.4K ﹤0.01% 1466

Other funds holding ORKA

VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Oppenheimer & Co's ORKA Position: Q3 2015 in Review

Oppenheimer & Co sold out of Oruka Therapeutics (ORKA) in Q3 2015, closing a stake of 20 shares — an estimated $35K sold.

Oppenheimer & Co first reported a position in ORKA in Q1 2015 and held it in 2 quarters. The position peaked at $35K in Q2 2015. 13 funds tracked by Wall St. Rank hold ORKA as of Q3 2015.

  • Oppenheimer & Co reported no remaining Oruka Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 20 Oruka Therapeutics shares in Q3 2015, an estimated $35K.
  • Oppenheimer & Co first reported a position in Oruka Therapeutics in Q1 2015 and held it in 2 quarters.
  • Oppenheimer & Co's Oruka Therapeutics position peaked at $35K in Q2 2015.
  • 13 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2015.

Based on Oppenheimer & Co's 13F filing for Q3 2015, filed 13 Nov 2015.